Shareholder Alert: Ademi LLP investigates whether Turning Point Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myer
prnewswire.com
news
2022-06-03 14:00:00

MILWAUKEE, June 3, 2022 /PRNewswire/ -- Ademi LLP is investigating Turning Point Therapeutics (NASDAQ:TPTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myer. 
Click here to learn how to join the action: https://www.ademilaw.com/case/turning-point-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.
Ademi LLP alleges Turning Point Therapeutics' financial outlook and prospects are excellent and yet Turning Point Therapeutics holders will receive only $76.
